A user's two month update on their hair loss journey and the treatments they are trying, which include exosome injections, minoxidil, finasteride, and RU58841.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.
This conversation is about "TheReedThomy's" 12-month long hair loss treatment regimen which includes finasteride, minoxidil, microneedling, nizoral, vitamins, and lifestyle changes. Other users have commented to congratulate him on his progress and ask questions about his results.
A user shared an 8-month update on their hair transplant surgery, which used 1800 grafts for aesthetic refinement, resulting in a natural-looking hairline and improved confidence. The procedure was performed by Dr. Abhinav Kumar, and the user is pleased with the results.
The user is experiencing continued hair loss despite using minoxidil, finasteride, tretinoin, and microneedling. They are considering a hair transplant due to lack of response to current treatments.
A 17-year-old shared progress pictures after using RU58841 and Minoxidil for 2 months, showing significant hair regrowth. Another user commented on the impressive results achieved in a short time.
A 21-year-old male shared his extensive hair loss treatment protocol, which includes Dutasteride, RU58841, Ketoconazole shampoo, oral Minoxidil, pyrilutamide, MK677, dermastamping, and castor oil, and reported improved hair regrowth and overall well-being. He has experienced no side effects and has also improved his diet and lifestyle.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.
A user started working with a leading hair cloning lab to address their hair loss. They have a computer science background and will assist with data science.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
A 32-year-old male has been dealing with hair loss since 2010 and started treatment 11 months ago. He used dutasteride, finasteride, minoxidil, multivitamins, vitamin D3, PRP, and a laser cap, resulting in improved hair density despite ongoing shedding.
The conversation discusses the anticipated release of GT20029, with some users expressing skepticism about its availability. It also mentions the use of treatments like Minoxidil, finasteride, RU58841, and dutasteride for hair loss.
A 22-year-old male has been using oral minoxidil, oral finasteride, microneedling, and ketoconazole for hair loss treatment over two years, experiencing some regrowth and maintenance. He reports side effects from finasteride, including erectile dysfunction, and slight libido impact from minoxidil.
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
The user improved their hair loss from stage 5 to stage 3 using Minoxidil, Finasteride, and a Dermapen. They saw results after 6 months, experienced a shedding phase, then saw more gains, advising others not to be discouraged during the shedding phase.
A 41-year-old shared their 195-day hair loss treatment progress using finasteride and minoxidil, initially topical and later oral, along with microneedling. They reported positive results and expressed satisfaction with the current regimen.
A user shared their 88-day progress using 1.25mg finasteride, topical minoxidil, and weekly 1mm microneedling, noting improvement from NW 4.5 to around NW 3. Another user complimented the progress.
The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.
The user is using dutasteride, oral and topical minoxidil, Nutrafol, Revita shampoo, ketoconazole shampoo, and a derma roller for hair regrowth. They plan to get a hair transplant next year.
KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
The user received 1600 hair grafts but is dissatisfied and plans a second transplant for better coverage. They use minoxidil and finasteride and are considering adding dutasteride.
The user is sharing their progress with hair loss using finasteride, minoxidil, and nizoral. They are seeking advice on what to do next for their hair. Some suggestions include switching to dutasteride, adding microneedling, or seeking another opinion from a dermatologist.
A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.
A user found a solution for Minoxidil-induced dandruff by using a custom NRF 11.121 mixture from a local pharmacy, which includes ingredients like Isopropyl palmitate and Cremophor RH 40. This formulation prevents dryness and allows better penetration when using hair shaders.
A 29-year-old is experiencing diffuse hair loss and has been using minoxidil without success. They are now trying a routine with oral minoxidil, topical finasteride, and dermarolling, but are unsure about the effectiveness and legitimacy of the products.